[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"FindCure Biosciences (ZhongShan) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,63,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100628981","early-phase-1-the-dosimetry-safety-and-diagnostic-efficacy-of-ga-fc516-in-healthy-subjects-and-patients-with-prostate-cancer-100628981",false,"NCT07468708","The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer","Evaluation of Dosimetry, Safety, Biodistribution and Preliminary Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer","Inclusion Criteria:\n\n1. Voluntarily participate the clinical study; sign the informed consent form;\n2. Aged 18 years or older;\n3. Cohort A: Healthy subjects;\n4. Cohort B: Patients with prostate cancer confirmed by histopathological or cytological diagnosis;\n\nExclusion Criteria:\n\n1. Severe impairment of liver, kidney, or cardiac function;\n2. Severe obesity or other conditions that prevent or make PET\u002FCT scanning impossible;\n3. Hypersensitivity to any active or inactive components of the study drug;\n4. Other subjects deemed unsuitable for enrollment by the investigators.",true,"MALE","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This goal of this study is to investigate the dosimetry, safety, biodistribution of ⁶⁸Ga-FC516. In this study, we will evaluate the safety, biodistribution and dosimetry of ⁶⁸Ga-FC516 in subjects and compared them with the results of ⁶⁸Ga-labeled prostate cancer-targeting tracer imaging to evaluate the dosimetric characteristics and diagnostic efficacy of ⁶⁸Ga-FC516.",[27,28],"Healthy Adult","Prostate Cancer","RECRUITING","2026-04-24",{"date":32,"type":33},"2026-04-29","ACTUAL",{"date":35,"type":33},"2026-03-09",{"date":37,"type":21},"2026-08",{"name":39,"class":40},"FindCure Biosciences (ZhongShan) Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100634645","early-phase-1-the-safety-dosimetry-and-efficacy-of-177lu-fc516-in-patients-with-prostate-cancer-100634645","NCT07542379","The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer","Evaluation of the Safety, Dosimetry and Efficacy of 177Lu-FC516 Injection in Patients With Prostate Cancer","Inclusion Criteria:\n\n1. Aged \\>=18 years old.\n2. Patients with metastatic castration-resistant prostate cancer who have failed standard treatments.\n3. According to RECIST 1.1, there is at least one measurable lesion.\n4. ECOG performance status 0-1.\n5. Laboratory examination should meet: ① Blood routine: hemoglobin (HGB) ≥90g\u002FL, neutrophil count (ANC) ≥1.5×10\\^9\u002FL, platelet count ( PLT) ≥100×10\\^9\u002FL; ②Blood biochemistry: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0×ULN, serum creatinine ( Cr)≤1.5×ULN or calculate the creatinine clearance ≥50 mL\u002Fmin according to the Cockcroft-Gault formula method.\n\nExclusion Criteria:\n\n1. Received anti-tumor therapy within 4 weeks before enrollment.\n2. Participated in other clinical trials within 4 weeks before enrollment and used clinical investigational drugs during this period.\n3. Have undergone surgery within 4 weeks before enrollment.\n4. Not recovered from the adverse reactions caused by previous anti-tumor treatments (≥CTCAE grade 1).\n5. Central nervous system metastases with clinical symptoms.\n6. With any situations that the researcher considers inappropriate to participate in this research.",{"count":50,"type":21},13,[24],"This study is a prospective, single-arm, open-label, dose-escalation study. A total of 5 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.",[28],"NOT_YET_RECRUITING","2026-04-14",{"date":57,"type":33},"2026-04-21",{"date":59,"type":21},"2026-04",{"date":61,"type":21},"2027-10",{"name":39,"class":40},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":18,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":41},"100628257","early-phase-1-the-safety-dosimetry-and-efficacy-of-177lu-inn805-in-patients-with-malignant-solid-tumors-100628257","NCT07459283","The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors","Evaluation of the Safety, Dosimetry and Efficacy of 177Lu-INN805 Injection in Patients With Malignant Solid Tumors","Inclusion Criteria:\n\n1. Aged 18 to 75 years old male and female.\n2. Patients with advanced malignant solid tumors who have failed standard treatments.\n3. According to RECIST 1.1, there is at least one measurable lesion.\n4. ECOG performance status 0-1.\n5. Laboratory examination should meet: ① Blood routine: hemoglobin (HGB) ≥90g\u002FL, neutrophil count (ANC) ≥1.5×10\\^9\u002FL, platelet count ( PLT) ≥100×10\\^9\u002FL; ②Blood biochemistry: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0×ULN, serum creatinine ( Cr)≤1.5×ULN or calculate the creatinine clearance ≥50 mL\u002Fmin according to the Cockcroft-Gault formula method\n\nExclusion Criteria:\n\n1. Received anti-tumor therapy within 4 weeks before enrollment.\n2. Participated in other clinical trials within 4 weeks before enrollment and used clinical investigational drugs during this period.\n3. Have undergone surgery within 4 weeks before enrollment.\n4. Not recovered from the adverse reactions caused by previous anti-tumor treatments (≥CTCAE grade 1).\n5. Central nervous system metastases with clinical symptoms.\n6. With any situations that the researcher considers inappropriate to participate in this research.","ALL","75 Years",{"count":20,"type":21},[24],"This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. The dosing schedule and dose could also be adjusted according to the patient's condition. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.",[76,77,78,79,80,81],"Maligant Solid Tumor","Head & Neck Cancer","Thyroid Cancer","Lung Cancer - Non Small Cell Squamous","Breast Cancer","Sarcoma","2026-03-08",{"date":84,"type":33},"2026-03-10",{"date":59,"type":21},{"date":87,"type":21},"2027-03",{"name":39,"class":40},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":70,"minAge":18,"maxAge":71,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":41},"100554458","phase-1-a-study-of-fc084csa-in-combination-of-tislelizumab-in-patients-with-advanced-malignant-solid-tumors-100554458","NCT06499350","A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n1. Aged 18 to 75 years old male and female.\n2. Phase Ib: Patients with histologically or cytologically diagnosed solid tumors who have failed standard therapy; Phase IIa: Patients with histologically or cytologically confirmed stage IIIB\u002FIIIC and stage IV NSCLC which surgery or radiotherapy cannot be performed.\n3. No known sensitizing mutations or other actionable oncogenes with approved therapies if available.\n4. Prior PD-1\u002FPD-L1 inhibitor combined with platinum-containing therapy failed;\n5. According to RECIST 1.1, there is at least one measurable lesion.\n6. ECOG performance status 0-1.\n7. Major organs are functioning well.\n\nExclusion Criteria:\n\n1. Not recovered from the adverse reactions caused by previous anti-tumor treatments (≥CTCAE grade 1).\n2. Received anti-tumor therapy within 4 weeks before enrollment.\n3. Participated in other clinical trials within 4 weeks before enrollment and used clinical investigational drugs during this period.\n4. Have undergone surgery within 4 weeks before enrollment, and the investigator believes that the patient's state has not recovered to the point where the study can be started.\n5. Patients with ascites (ascites), pleural effusion (pleural effusion) or pericardial effusion that cannot be controlled by drainage or other methods.\n6. Central nervous system metastases with clinical symptoms.\n7. With any situations that the researcher considers inappropriate to participate in this research.",{"count":97,"type":21},33,[99,100],"PHASE1","PHASE2","The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.",[103],"Advanced Malignant Solid Tumors",{"date":84,"type":33},{"date":106,"type":33},"2024-11-13",{"date":108,"type":21},"2026-10-01",{"name":39,"class":40},""]